Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01578837 | Combined Rg3-enriched Korean Red Ginseng and American Ginseng in the Management of Hypertension in Type 2 Diabetes | PHASE1 | COMPLETED | 90 | — | — | Apr 1, 2014 | Sep 1, 2017 | Nov 21, 2018 | 2 | Canada, Croatia |
| Arm | Type | Description |
|---|---|---|
| Ginseng | EXPERIMENTAL | Combined Rg3-enriched Korean Red Ginseng and American Ginseng capsule |
| Wheat Bran | PLACEBO_COMPARATOR | 100 % Natural Wheat Bran capsule |
| Name | Type | Description |
|---|---|---|
| Ginseng | DIETARY_SUPPLEMENT | 2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day). |
| Wheat Bran | DIETARY_SUPPLEMENT | 2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day). |
Inclusion Criteria: * between the age of 40 and 75 years * type 2 diabetes (at least 1 year duration, HbA1c ≥ 6.5%- ≤ 8.0%, treated with diet and/or oral hypoglycemic medications) * clinically diagnosed and treated hypertension according to Canadian Diabetes Association Clinical Practice Guidelines...